Literature DB >> 17872587

Relapse after treatment with peginterferon alpha-2b alone or in combination with lamivudine in HBeAg positive chronic hepatitis B.

H J Flink, E H C J Buster, I Merican, F Nevens, G Kitis, J Cianciara, R A de Vries, B E Hansen, S W Schalm, H L A Janssen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17872587      PMCID： PMC2000267          DOI： 10.1136/gut.2007.125633

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  9 in total

1.  Long-term remission of chronic hepatitis B after alpha-interferon therapy.

Authors:  J Korenman; B Baker; J Waggoner; J E Everhart; A M Di Bisceglie; J H Hoofnagle
Journal:  Ann Intern Med       Date:  1991-04-15       Impact factor: 25.391

2.  Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase.

Authors:  A B van Nunen; B E Hansen; D J Suh; H F Löhr; L Chemello; H Fontaine; J Heathcote; B C Song; H L A Janssen; R A de Man; S W Schalm
Journal:  Gut       Date:  2003-03       Impact factor: 23.059

3.  Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.

Authors:  Harry L A Janssen; Monika van Zonneveld; Hakan Senturk; Stefan Zeuzem; Ulus S Akarca; Yilmaz Cakaloglu; Christopher Simon; Thomas M K So; Guido Gerken; Robert A de Man; Hubert G M Niesters; Pieter Zondervan; Bettina Hansen; Solko W Schalm
Journal:  Lancet       Date:  2005 Jan 8-14       Impact factor: 79.321

4.  Long-term results of lamivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B: response and relapse rates, and factors related to durability of HBeAg seroconversion.

Authors:  Seung Kew Yoon; Jeong Won Jang; Chang Wook Kim; Si Hyun Bae; Jong Young Choi; Sang Wook Choi; Young Sok Lee; Chang Don Lee; Kyu Won Chung; Hee Sik Sun; Boo Sung Kim
Journal:  Intervirology       Date:  2005       Impact factor: 1.763

5.  Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

Authors:  George K K Lau; Teerha Piratvisuth; Kang Xian Luo; Patrick Marcellin; Satawat Thongsawat; Graham Cooksley; Edward Gane; Michael W Fried; Wan Cheng Chow; Seung Woon Paik; Wen Yu Chang; Thomas Berg; Robert Flisiak; Philip McCloud; Nigel Pluck
Journal:  N Engl J Med       Date:  2005-06-30       Impact factor: 91.245

6.  Predicting relapse after cessation of Lamivudine monotherapy for chronic hepatitis B virus infection.

Authors:  Kiyoaki Ito; Yasuhito Tanaka; Etsuro Orito; Noboru Hirashima; Tatsuya Ide; Teruko Hino; Ryukichi Kumashiro; Atunaga Kato; Haruhiko Nukaya; Kenji Sakakibara; Motokazu Mukaide; Hidemi Ito; Michio Sata; Ryuzo Ueda; Masashi Mizokami
Journal:  Clin Infect Dis       Date:  2004-01-30       Impact factor: 9.079

7.  Antiviral effect of prolonged intermittent lymphoblastoid alpha interferon treatment in chronic hepatitis B.

Authors:  H L Janssen; L Berk; S W Schalm; R A Heijtink; G Hess; S Rossol; K H Meyer zum Buschenfelde; R A Chamuleau; P L Jansen; H W Reesink
Journal:  Gut       Date:  1992-08       Impact factor: 23.059

8.  Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.

Authors:  Monika van Zonneveld; Pieter Honkoop; Bettina E Hansen; Hubertus G M Niesters; Sarwa Darwish Murad; Robert A de Man; Solko W Schalm; Harry L A Janssen
Journal:  Hepatology       Date:  2004-03       Impact factor: 17.425

9.  Which patients with chronic hepatitis B are more likely to relapse after interferon alpha-induced hepatitis B e antigen loss in Korea?

Authors:  Byung-Cheol Song; Dong Jin Suh; Han Chu Lee; Young-Hwa Chung; Yung Sang Lee
Journal:  J Clin Gastroenterol       Date:  2004-02       Impact factor: 3.062
  9 in total
  2 in total

Review 1.  Current prophylactic strategies against hepatitis B virus recurrence after liver transplantation.

Authors:  Li Jiang; Li-Sheng Jiang; Nan-Sheng Cheng; Lu-Nan Yan
Journal:  World J Gastroenterol       Date:  2009-05-28       Impact factor: 5.742

2.  Study on Post-Treatment Relapse in HBeAg Positive CHB Patients.

Authors:  Junfeng Lu; Jin'e Li; Yali Liu; Shan Ren; Zhenhuan Cao; Yi Jin; Lina Ma; Chengli Shen; Xinyue Chen
Journal:  PLoS One       Date:  2015-11-02       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.